Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion for Itovebi, in combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. If approved, the Itovebi-based regimen has the potential to transform the standard of care in this first-line setting, where treatments are currently limited. A final decision regarding the approval is expected from the European Commission in the near future.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech announces two-year follow-up data from STARGLO study
- Roche’s Genentech announces FDA approval of Susvimo for diabetic retinopathy
- Trump Trade: White House announces ‘Golden Dome’ missile-defense shield
- Roche provides update on FDA Advisory Committee meeting on Columvi combination
- HHS says ‘taking immediate steps to implement’ Trump drug pricing order